{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-033463","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.798355+00:00","generated_at":"2026-05-26T05:23:18.866385+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"BioMarin appoints Timothy Walbert to board, expanding size to 12 members","bullets":["Board increased from 11 to 12 members; Walbert appointed effective February 24, 2025.","Walbert receives standard independent director compensation including pro rata RSU grant (annual award $400,000).","No committee assignments at this time; standard indemnification agreement to be entered into."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-033463","json":"https://secwatch.observer/filing/0001193125-25-033463.json","markdown":"https://secwatch.observer/filing/0001193125-25-033463.md","text":"https://secwatch.observer/filing/0001193125-25-033463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525033463/0001193125-25-033463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525033463/d876806d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:23:18.866385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d5e858da5","claim":"Timothy P. Walbert was appointed as Director at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525033463/0001193125-25-033463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}